Inactivation of the Mouse Huntington's Disease Gene Homolog Hdh
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Huntington's disease (HD) is a dominant neurodegenerative disorder caused by expansion of a CAG repeat in the gene encoding huntingtin, a protein of unknown function. To distinguish between "loss of function" and "gain of function" models of HD, the murine HD homolog Hdh was inactivated by gene targeting. Mice heterozygous for Hdh inactivation were phenotypically normal, whereas homozygosity resulted in embryonic death. Homozygotes displayed abnormal gastrulation at embryonic day 7.5 and were resorbing by day 8.5. Thus, huntingtin is critical early in embryonic development, before the emergence of the nervous system. That Hdh inactivation does not mimic adult HD neuropathology suggests that the human disease involves a gain of function.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar to α-syn in PD and Tau in AD, polyQ-HTT aggregates exert toxic gain-of-function effects, forming β-sheet-rich structures that disrupt essential cellular pathways and cause neurotoxicity [169,170].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [169]
In the citing paper
“Similar to α-syn in PD and Tau in AD, polyQ-HTT aggregates exert toxic gain-of-function effects, forming β-sheet-rich structures that disrupt essential cellular pathways and cause neurotoxicity [169,170].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [169]
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Self-citationVerkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481
Derivation of completely cell culture-derived mice from early-passage embryonic stem cells.
Nagy, A., Rossant, J., Nagy, R., Abramow-Newerly, W., & Roder, J. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8424 · Cited by 2,329
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Self-citationAbsence of expression of the FMR-1 gene in fragile X syndrome
Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S. T., Oostra, B. A., Caskey, C. T., & Nelson, D. L. (1991) · Cell · doi:10.1016/0092-8674(91)90125-i · Cited by 1,476
Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene
Tybulewicz, V. L. J., Crawford, C. E., Jackson, P. K., Bronson, R. T., & Mulligan, R. C. (1991) · Cell · doi:10.1016/0092-8674(91)90011-m · Cited by 1,281
Fmr1 knockout mice: A model to study fragile X mental retardation
THEDUTCHBELGIANFRAGILEXCONSOR (1994) · Cell · doi:10.1016/0092-8674(94)90569-x · Cited by 1,035
Nasir, J., Floresco, S. B., O'Kusky, J. R., Diewert, V. M., Richman, J. M., Zeisler, J., Borowski, A., Marth, J. D., Phillips, A. G., & Hayden, M. R. (1995) · Cell · doi:10.1016/0092-8674(95)90542-1 · Cited by 872
Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons
DiFiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young, C., Martin, E., Vonsattel, J.-P., Carraway, R., Reeves, S. A., et al. (1995) · Neuron · doi:10.1016/0896-6273(95)90346-1 · Cited by 749
Self-citationDNA methylation represses FMR-1 transcription in fragile X syndrome
Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe, D., & Warren, S. T. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.6.397 · Cited by 680
Research works printed but not linked: 3
- CELL 78: 23 (1994).
- Nagy, A., Gene Targeting: A Practical Approach: 147 (1993).
- Wurst, W., Gene Targeting: A Practical Approach: 31 (1993).
Cited by
Items 301–400 of 885
Huntingtin promotes cell survival by preventing Pak2 cleavage
Luo, S., & Rubinsztein, D. C. (2009) · Journal of Cell Science · doi:10.1242/jcs.050013 · Cited by 56
Bidirectional Control of Postsynaptic Density-95 (PSD-95) Clustering by Huntingtin
Parsons, M. P., Kang, R., Buren, C., Dau, A., Southwell, A. L., Doty, C. N., Sanders, S. S., Hayden, M. R., & Raymond, L. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.513945 · Cited by 56
Axonopathy in Huntington's disease
Li, J.-Y., & Conforti, L. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.08.010 · Cited by 55
Antibody-based therapies for Huntington’s disease: current status and future directions
Denis, H. L., David, L. S., & Cicchetti, F. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104569 · Cited by 55
Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.
Martin, B., Golden, E., Keselman, A., Stone, M., Mattson, M. P., Egan, J. M., & Maudsley, S. R. (2008) · PubMed · doi:10.14670/hh-23.237 · Cited by 55
CAG trinucleotide RNA repeats interact with RNA-binding proteins.
McLaughlin, B., Spencer, C. M., & Eberwine, J. H. (1996) · PubMed · Cited by 55
Pharmaceutical, cellular and genetic therapies for Huntington's disease
Handley, O., Naji, J. J., Dunnett, S. B., & Rosser, A. (2005) · Clinical Science · doi:10.1042/cs20050148 · Cited by 55
Lisowski, P., Lickfett, S., Rybak‐Wolf, A., Menacho, C., Le, S., Pentimalli, T. M., Notopoulou, S., Dykstra, W., Oehler, D., López-Calcerrada, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51216-w · Cited by 54
Delivering a disease-modifying treatment for Huntington's disease
Godinho, B. M. D. C., Malhotra, M., O’Driscoll, C. M., & Cryan, J. F. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.09.011 · Cited by 54
Genetic Mouse Models of Neurodegenerative Diseases
Trancikova, A. K., Ramonet, D., & Moore, D. J. (2011) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-384878-9.00012-1 · Cited by 54
Recent advances in Huntingtonʼs disease: implications for experimental therapeutics
Feigin, A., & Zgaljardic, D. J. (2002) · Current Opinion in Neurology · doi:10.1097/00019052-200208000-00013 · Cited by 54
Huntington’s disease: nearly four decades of human molecular genetics
Gusella, J. F., Lee, J., & MacDonald, M. E. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab170 · Cited by 53
Self-citationSawa, A. (2001) · Journal of Molecular Medicine · doi:10.1007/s001090100223 · Cited by 53
Huntingtin is required for normal hematopoiesis
Metzler, M., Helgason, C. D., Dragatsis, I., Zhang, T., Gan, L., Pineault, N., Zeitlin, S. O., Humphries, R. K., & Hayden, M. R. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.3.387 · Cited by 53
Familial conformational diseases and dementias
Crowther, D. C. (2002) · Human Mutation · doi:10.1002/humu.10100 · Cited by 52
Crosstalk between huntingtin and syntaxin 1A regulates N-type calcium channels
Swayne, L. A., Chen, L., Hameed, S., Barr, W., Charlesworth, E., Colicos, M. A., Zamponi, G. W., & Braun, J. E. A. (2005) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.07.016 · Cited by 52
Life Without Huntingtin: Normal Differentiation into Functional Neurons
Metzler, M., Chen, N., Helgason, C. D., Graham, R. K., Nichol, K., McCutcheon, K. M., Nasir, J., Humphries, R. K., Raymond, L. A., & Hayden, M. R. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721009.x · Cited by 52
The N17 domain mitigates nuclear toxicity in a novel zebrafish Huntington’s disease model
Veldman, M. B., Ríos, Y., Lu, X., Gu, X., Qin, W., Li, S., Yang, X. W., & Lin, S. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0063-2 · Cited by 51
The effects of huntingtin-lowering: what do we know so far?
Kaemmerer, W. F., & Grondin, R. (2019) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s163808 · Cited by 51
Prevention of cytosolic IAPs degradation: a potential pharmacological target in Huntington's Disease
Goffredo, D., Rigamonti, D., Zuccato, C., Tartari, M., Valenza, M., & Cattaneo, E. F. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2005.01.006 · Cited by 51
Sousa, C. M., McGuire, J. R., Thion, M. S., Gentien, D., de la Grange, P., du Montcel, S. T., Vincent‐Salomon, A., Dürr, A., & Humbert, S. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201546 · Cited by 51
Bradley, S. V., Hyun, T. S., Oravecz-Wilson, K. I., Li, L., Waldorff, E. I., Ermilov, A. N., Goldstein, S. A., Zhang, C. X., Drubin, D. G., Varela, K., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm076 · Cited by 48
Conforti, P., Camnasio, S., Mutti, C., Valenza, M., Thompson, M., Fossale, E., Zeitlin, S., MacDonald, M. E., Zuccato, C., & Cattaneo, E. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.10.015 · Cited by 42
Self-citationThe regulation of N-terminal Huntingtin (Htt552) accumulation by Beclin1
Wu, J.-C., Qi, L., Wang, Y., Kegel, K. B., Yoder, J., Difiglia, M., Qin, Z.-H., & Lin, F. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.14 · Cited by 51
Studying polyglutamine diseases in Drosophila
Xu, Z., Tito, A. J., Rui, Y., & Zhang, S. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.08.002 · Cited by 50
Dragatsis, I., Zeitlin, S., & Dietrich, P. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh328 · Cited by 45
Page, K. J., Potter, L., Aronni, S., Everitt, B. J., & Dunnett, S. B. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00185.x · Cited by 50
Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic
Miniarikova, J., Evers, M. M., & Konstantinova, P. S. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.002 · Cited by 49
Functional analysis of the Huntington's disease (HD) gene promoter
Coles, R., Caswell, R., & Rubinsztein, D. C. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.5.791 · Cited by 49
Striatal circuit development and its alterations in Huntington's disease
Lebouc, M., Richard, Q., Garret, M., & Baufreton, J. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105076 · Cited by 48
Inositol 1,4,5-tripshosphate receptor, calcium signalling and huntington’s disease
Борисович, Б. И. (2007) · Springer eBooks · doi:10.1007/978-1-4020-6191-2_11 · Cited by 48
Huntingtin Interactions with Membrane Phospholipids: Strategic Targets for Therapeutic Intervention?
Kegel-Gleason, K. B. (2013) · Journal of Huntington's Disease · doi:10.3233/jhd-130068 · Cited by 39
An upstream open reading frame impedes translation of the huntingtin gene
Lee, J., Park, E. H., Couture, G., Harvey, I., Garneau, P., & Pelletier, J. (2002) · Nucleic Acids Research · doi:10.1093/nar/gkf664 · Cited by 48
Kerkis, I., Haddad, M. S., Valverde, C. W., & Glosman, S. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0248-1 · Cited by 47
Salivary levels of total huntingtin are elevated in Huntington’s disease patients
Corey‐Bloom, J., Haque, A. S., Park, S., Nathan, A. S., Baker, R. W., & Thomas, E. A. (2018) · Scientific Reports · doi:10.1038/s41598-018-25095-3 · Cited by 47
Iennaco, R., Formenti, G., Trovesi, C., Rossi, R. L., Zuccato, C., Lischetti, T., Bocchi, V. D., Scolz, A., Martínez‐Labarga, C., Rickards, O., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-021-00914-9 · Cited by 47
Cell-autonomous and non-cell-autonomous toxicity in polyglutamine diseases
Sambataro, F., & Pennuto, M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.10.003 · Cited by 47
Huntingtin is required for ciliogenesis and neurogenesis during early Xenopus development
Haremaki, T., Deglincerti, A., & Brivanlou, A. H. (2015) · Developmental Biology · doi:10.1016/j.ydbio.2015.07.013 · Cited by 47
Iodoacetate Produces Striatal Excitotoxic Lesions
Matthews, R. T., Ferrante, R. J., Jenkins, B. G., Browne, S. E., Goetz, K., Berger, S. A., Chen, Y. I., & Beal, M. F. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010285.x · Cited by 47
3 The Organizer of the Gastrulating Mouse Embryo
Camus, A., & Tam, P. (1999) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(08)60315-4 · Cited by 46
Kim, M., Velier, J. J., Chase, K. O., Laforet, G. A., Kalchman, M. A., Hayden, M. R., Won, L., Heller, A., Aronin, N., & DiFiglia, M. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00400-x · Cited by 46
Huntington's disease: the past, present, and future search for disease modifiers.
Clabough, E. B. D. (2013) · PubMed Central · Cited by 45
Caspase substrates and neurodegenerative diseases
Bulat, N., & Widmann, C. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.07.007 · Cited by 45
Lee, D., Liu, J., Junn, H. J., Lee, E., Jeong, K.-S., & Seol, D. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0334-z · Cited by 45
Estevez‐Fraga, C., Altmann, A., Parker, C. S., Scahill, R. I., Costa, B., Chen, Z., Manzoni, C., Zarkali, A., Dürr, A., Roos, R. A. C., et al. (2023) · Brain · doi:10.1093/brain/awad275 · Cited by 45
Clark, G. J., Cooper, B., Fitzpatrick, S., Green, B. J., & Hart, D. N. J. (2001) · Tissue Antigens · doi:10.1034/j.1399-0039.2001.057005415.x · Cited by 45
Kerschbamer, E., & Biagioli, M. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00509 · Cited by 44
Madison, J. L., Węgrzynowicz, M., Aschner, M., & Bowman, A. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031024 · Cited by 44
Pérez‐Navarro, E., Canals, J. M., Ginés, S., & Alberch, J. (2006) · PubMed · doi:10.14670/hh-21.1217 · Cited by 44
Early mouse development: lessons from gene targeting
St‐Jacques, B., & McMahon, A. P. (1996) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(96)80065-7 · Cited by 44
Tousley, A. R., Iuliano, M., Weisman, E., Sapp, E., Richardson, H., Vodička, P., Alexander, J. S., Aronin, N., DiFiglia, M., & Kegel-Gleason, K. B. (2019) · PLoS ONE · doi:10.1371/journal.pone.0212337 · Cited by 44
Synaptic pathology in Huntington's disease: Beyond the corticostriatal pathway
Barry, J., Bui, M. T. N., Levine, M. S., & Cepeda, C. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105574 · Cited by 43
DRPLA gene (Atrophin-1) sequence and mRNA expression in human brain
Margolis, R. L., Li, S.-H., Young, W. S., Wagster, M. V., Stine, O. C., Kidwai, A. S., Ashworth, R. G., & Ross, C. A. (1996) · Molecular Brain Research · doi:10.1016/0169-328x(95)00241-j · Cited by 43
Hickman, R. A., Faust, P. L., Rosenblum, M. K., Marder, K. S., Mehler, M. F., & Vonsattel, J. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02269-4 · Cited by 42
Self-citationEpigenetic regulation in Huntington's disease
Hyeon, J. W., Kim, A. H., & Yano, H. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105074 · Cited by 42
Suppression of MAPK11 or HIPK3 reduces mutant Huntingtin levels in Huntington's disease models
Yu, M., Fu, Y., Liang, Y., Song, H., Yao, Y., Wu, P., Yao, Y., Pan, Y., Wen, X., Ma, L., et al. (2017) · Cell Research · doi:10.1038/cr.2017.113 · Cited by 41
Antisense therapies for movement disorders
Scoles, D. R., & Pulst, S. M. (2019) · Movement Disorders · doi:10.1002/mds.27782 · Cited by 41
Oligodendrocyte pathology in Huntington’s disease: from mechanisms to therapeutics
Bardile, C. F., Radulescu, C. I., & Pouladi, M. A. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.07.010 · Cited by 41
Gene-Targeting Technologies for the Study of Neurological Disorders
Beglopoulos, V., & Shen, J. (2004) · NeuroMolecular Medicine · doi:10.1385/nmm:6:1:013 · Cited by 41
Ross, C. A., Margolis, R. L., Bêcher, M. W., Wood, J. D., Engelender, S., Cooper, J. K., & Sharp, A. H. (1998) · Progress in brain research · doi:10.1016/s0079-6123(08)64029-7 · Cited by 41
Molecular Neurobiology and Genetics: Investigation of Neural Function and Dysfunction
Green, T., Heinemann, S. F., & Gusella, J. F. (1998) · Neuron · doi:10.1016/s0896-6273(00)80986-1 · Cited by 41
Self-citationYeast buddies helping to unravel the complexity of neurodegenerative disorders
Fruhmann, G., Seynnaeve, D., Zheng, J., Ven, K., Molenberghs, S., Wilms, T., Liu, B., Winderickx, J., & Franssens, V. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.05.002 · Cited by 40
Linking SNPs to CAG repeat length in Huntington's disease patients
Liu, W., Kennington, L. A., Rosas, H. D., Hersch, S. M., Cha, J.-H. J., Zamore, P. D., & Aronin, N. (2008) · Nature Methods · doi:10.1038/nmeth.1261 · Cited by 40
Reiner, A. J., Mar, N. D., Deng, Y., Meade, C. A., Sun, Z., & Goldowitz, D. (2007) · The Journal of Comparative Neurology · doi:10.1002/cne.21515 · Cited by 40
[Huntington disease. A review].
Bonilla, E. (2000) · PubMed · Cited by 40
Inhibition of Huntingtin Synthesis by Antisense Oligodeoxynucleotides
Nellemann, C., Abell, K., Nørremølle, A., Løkkegaard, T., Naver, B., Röpke, C., Rygaard, J., Sørensen, S. A., & Hasholt, L. (2000) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0872 · Cited by 40
Molecular Mechanisms Underlying Muscle Wasting in Huntington’s Disease
Bozzi, M., & Sciandra, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218314 · Cited by 39
Yang, L., Su, Z., Wang, Z., Li, Z., Shang, Z., Du, H., Liu, G., Qi, D., Yang, Z., Xu, Z., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03552-8 · Cited by 39
Huntington's Disease: An Immune Perspective
Nayak, A., Ansar, R., Verma, S. K., Bonifati, D. M., & Kishore, U. (2011) · Neurology Research International · doi:10.1155/2011/563784 · Cited by 39
Hughes, A. C., Mort, M. E., Elliston, L. A., Thomas, R. M., Brooks, S. P., Dunnett, S. B., & Jones, L. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.12.028 · Cited by 39
Omi, K., Hachiya, N., Tokunaga, K., & Kaneko, K. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.10.061 · Cited by 39
Unconventional Secretion and Intercellular Transfer of Mutant Huntingtin
Tang, B. L. (2018) · Cells · doi:10.3390/cells7060059 · Cited by 38
Schiefner, A., Chatwell, L., Körner, J., Neumaier, I., Colby, D. W., Volkmer, R., Wittrup, K. D., & Skerra, A. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.09.034 · Cited by 38
Use of human stem cells in Huntington disease modeling and translational research
Golas, M. M., & Sander, B. O. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.01.021 · Cited by 38
Triplet repeat disorders: discussion of molecular mechanisms
Timchenko, L., & Caskey, C. T. (1999) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050383 · Cited by 38
In-vivo evidence for the disruption of Rab11 vesicle transport by loss of huntingtin
Power, D., Srinivasan, S., & Gunawardena, S. (2012) · Neuroreport · doi:10.1097/wnr.0b013e328359d990 · Cited by 37
Mutations causing Lopes-Maciel-Rodan syndrome are huntingtin hypomorphs
Jung, R., Lee, Y., Barker, D., Correia, K., Shin, B., Loupe, J. M., Collins, R. L., Lucente, D. E., Ruliera, J., Gillis, T., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddaa283 · Cited by 37
Self-citationProbing the Huntingtin 1-17 Membrane Anchor on a Phospholipid Bilayer by Using All-Atom Simulations
Côté, S., Binette, V., Salnikov, E. S., Bechinger, B., & Mousseau, N. (2015) · Biophysical Journal · doi:10.1016/j.bpj.2015.02.001 · Cited by 37
The role of DNA base excision repair in brain homeostasis and disease
Akbari, M., Morevati, M., Croteau, D., & Bohr, V. A. (2015) · DNA Repair · doi:10.1016/j.dnarep.2015.04.029 · Cited by 34
Reduced Levels of Proteasome Products in a Mouse Striatal Cell Model of Huntington’s Disease
Dasgupta, S., Fishman, M. A., Mahallati, H., Castro, L. M., Tashima, A. K., Ferro, E. S., & Fricker, L. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145333 · Cited by 37
Schimenti, J. C., Libby, B. J., Bergstrom, R. A., Wilson, L. A., Näf, D., Tarantino, L. M., Alavi, A., Lengeling, A., & Bućan, M. (2000) · Genome Research · doi:10.1101/gr.10.7.1043 · Cited by 37
Unstable mutations and neurodegenerative disorders
Brice, A. (1998) · Journal of Neurology · doi:10.1007/s004150050234 · Cited by 37
Szlachcic, W. J., Wiatr, K., Trzeciak, M., Figlerowicz, M., & Figiel, M. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00253 · Cited by 36
Pradhan, S., Gao, R., Bush, K. M., Zhang, N., Wairkar, Y. P., & Sarkar, P. S. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.837576 · Cited by 36
AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington’s disease mouse model
Thomson, S. B., Stam, A., Brouwers, C. C., Fodale, V., Bresciani, A., Vermeulen, M., Mostafavi, S., Petkau, T. L., Hill, A., Yung, A. C., et al. (2022) · Brain · doi:10.1093/brain/awac458 · Cited by 36
Wang, L., & Qin, Z. (2006) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00410.x · Cited by 36
Latest advances on new promising molecular-based therapeutic approaches for Huntington’s disease
Cheng, Y., Zhang, S., & Shang, H. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2023-0142 · Cited by 35
Therapeutic approaches to preventing cell death in Huntington disease
Kaplan, A. R., & Stockwell, B. R. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.08.004 · Cited by 35
Hexosamine Pathway Activation Improves Protein Homeostasis through the Integrated Stress Response
Horn, M., Denzel, S. I., Srinivasan, B., Allmeroth, K., Schiffer, I., Karthikaisamy, V., Miethe, S., Breuer, P., Antebi, A., & Denzel, M. S. (2020) · iScience · doi:10.1016/j.isci.2020.100887 · Cited by 35
Casale, A. M., Liguori, F., Ansaloni, F., Cappucci, U., Finaurini, S., Spirito, G., Persichetti, F., Sanges, R., Gustincich, S., & Piacentini, L. (2021) · iScience · doi:10.1016/j.isci.2021.103702 · Cited by 36
Self-citationAccessing the genomic effects of naked nanoceria in murine neuronal cells
Lee, T., Raitano, J. M., Rennert, O. M., Chan, S., & Chan, W. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.08.005 · Cited by 35
Cepeda, C., Oikonomou, K. D., Cummings, D. M., Barry, J., Yazon, V.-W., Chen, D. T., Asai, J., Williams, C. K., & Vinters, H. V. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24503 · Cited by 35
Zhang, H., Das, S., Li, Q., Dragatsis, I., Repa, J. J., Zeitlin, S. O., Hajnóczky, G., & Борисович, Б. И. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-38 · Cited by 35
Transgenic mouse models of neurodegenerative disease caused by CAG/polyglutamine expansions
Bates, G. P., & Davies, S. W. (1997) · Molecular Medicine Today · doi:10.1016/s1357-4310(97)01142-8 · Cited by 35
Interacting proteins as genetic modifiers of Huntington disease
Li, X., Friedman, M. J., & Li, S. (2007) · Trends in Genetics · doi:10.1016/j.tig.2007.07.007 · Cited by 34
Huntingtin interacting protein HYPK is intrinsically unstructured
Raychaudhuri, S., Majumder, P., Sarkar, S., Giri, K., Mukhopadhyay, D., & Bhattacharyya, N. P. (2007) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21856 · Cited by 34
Ryan, A. B., Zeitlin, S. O., & Scrable, H. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.002 · Cited by 33
Self-citationThe Yin and Yang of nucleic acid-based therapy in the brain
Gustincich, S., Zucchelli, S., & Mallamaci, A. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.11.001 · Cited by 33
Matsuyama, N., Hadano, S., Onoe, K., Osuga, H., Showguchi-Miyata, J., Gondo, Y., & Ikeda, J. (2000) · Genomics · doi:10.1006/geno.2000.6317 · Cited by 33
Thadke, S. A., Perera, J. D. R., Hridya, V. M., Bhatt, K. S., Shaikh, A. Y., Hsieh, W., Chen, M., Gayathri, C., Gil, R. R., Rule, G. S., et al. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00062 · Cited by 33
Metadata
- Authors
- Duyao, M. P., Auerbach, A. B., Ryan, A., Persichetti, F., Barnes, G. T., McNeil, S. M., Ge, P., Vonsattel, J.-P., Gusella, J. F., Joyner, A. L., & MacDonald, M. E.
- Affiliations
- Massachusetts General Hospital (US)
- Mount Sinai Hospital (CA)
- Corresponding author
- MacDonald, Marcy E.
- Venue
- Science
- Published
- 1995-07-21
- Volume
- 269
- Issue
- 5222
- Pages
- 407-410
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2002644780
- Cited by
- 723
- References
- 29
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 15 · 2023: 16 · 2022: 18 · 2021: 26 · 2020: 20 · 2019: 22 · 2018: 20 · 2017: 26 · 2016: 20 · 2015: 21 · 2014: 33 · 2013: 22 · 2012: 32
- FWCI
- 12.12
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Neurological Disorders and Stroke (NS 16367, NS32765, R01NS032765)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
- Keywords
- Huntington's disease, huntingtin, gene targeting, embryonic lethality, gastrulation, loss of function, gain-of-function, CAG repeat expansion, mouse model, neurodegeneration
- MeSH terms
- Huntingtin Protein, Animals, Base Sequence, Cell Line, Ectoderm, Female, Embryonic and Fetal Development, Genotype, Heterozygote, Homozygote, Humans, Huntington Disease, Male, Mesoderm, Mice, Inbred C57BL, Molecular Sequence Data, Nerve Tissue Proteins, Nuclear Proteins, Phenotype, Stem Cells, Gene Targeting, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.